Baker Avenue Asset Management, LP
Position in NBIX — Neurocrine Biosciences Inc
CIK 1432529
SAN FRANCISCO, CA
Position in NBIX
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$594,946
+$108,826 QoQ
Shares Held
3,530
-4.3% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#447
of 768 holders
Holding Since
Dec 2022
6 quarters on record
Voting authority
Sole 30%
Shared 0%
None 70%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Baker Avenue Asset Management, LP holds $2,054,749 across 6 Drug Manufacturers - Specialty & Generic names. NBIX ranks #1 (29.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
This page
|
3,530 | $594,946 | |
| 2 | PBH |
Prestige Consumer Healthcare Inc.
|
9,702 | $458,613 | |
| 3 | ELAN |
Elanco Animal Health Inc
|
13,344 | $328,395 | |
| 4 | ZTS |
Zoetis Inc.
|
4,507 | $323,873 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
446 | $241,656 | |
| 6 | PRGO |
PERRIGO Co plc
|
10,324 | $107,266 |
All Filings in NBIX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $594,946 | 3,530 | Shares | Sole | 2026-07-28 | |
| 2026-03-31 | $486,120 | 3,690 | Shares | Sole | 2026-05-12 | |
| 2023-09-30 | $7,650 | 68 | Shares | Sole | 2023-11-15 | |
| 2023-06-30 | $1,225 | 13 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $1,619 | 16 | Shares | Sole | 2023-05-16 | |
| 2022-12-31 | $3,702 | 31 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||